Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations

Media contact:




Investor contact:




...

Related Keywords

France ,Beerse ,Region Flamande ,Belgium ,Saclay ,France General ,Institut Curie ,Henar Hevia ,Nicolas Girard ,Zayn Qureshi ,European Medicines Agency ,Johnson ,Janssen Cilag International ,Paris Saclay University ,Committee For Medicinal Products Human Use ,Cilag International ,Medicinal Products ,Human Use ,Professor Nicolas Girard ,Medical Oncology ,Thoracic Oncology ,Respiratory Medicine ,Senior Director ,Area Lead ,Johnson Innovative ,Markets ,